A care home worker from Abingdon was among the winners at a charity awards ceremony held in Oxfordshire last night.
Jeff Denton was recognised at the Against Breast Cancer Achievement Awards - which celebrates the success and achievements of groups and indivduals across Berkshire, Buckinghamshire and Oxfordshire.
Our very own reporter Mel Bloor was there to host the awards....
The Hampshire town of Fleet is being painted pink in aid of the Frimley Park Hospital Breast Care Appeal. It will last from 10 to 17 October.
Kim Knight and Sally Herman had the idea following the success of last year’s Fleet fashion week. With the support of Fleet businesses and a few celebrities, they have organised a series of events in the town.
Kim said “We wanted to paint our town pink to thank the amazing breast care team at Frimley Park Hospital and to raise awareness of the high incidence of breast cancer in our local community.
"The new breast care unit and 3D mammography machine that the appeal is providing will benefit so many people in our area - and this is an opportunity for everyone to get on board and support it.”
Six women have been diagnosed with breast cancer after a review of assessments made in Oxfordshire.
Thirty women were recalled following concerns over screenings for the disease made by the same radiologist. They were identified by Oxford University Hospitals NHS Trust after a review of the 626 women seen between 2011 and 2014.
A formal investigation has been carried out by Public Health England, the NHS Breast Screening Programme and the Trust. A statement confirmed that a radiologist had not undertaken assessments since the outset of investigation.
A firm of solicitors is holding an open day on 8 January for women who may be concerned and seeking legal support.
Video report. A ten-year-old golden Labrador has been trained to become a medical detection dog - after sniffing our breast cancer in her owner.
It is Breast Cancer Awareness Month and a woman from Brighton is documenting her battle with the disease, as well as raising awareness and thousands for charity, by shaving her hair and wearing different 'head gear' each day.
Andy Dickenson reports. You can sponsor Sara Cutting here.
A woman from Brighton who was diagnosed with breast cancer in July has had her head shaved for charity. Sara Cutting is hoping to raise awareness of the condition and its impact. She is wearing a different sort of 'headgear' every day.
Former breast cancer patients and those recently diagnosed with the disease - have begun a campaign to build a new specialist unit in Wiltshire.
Three quarters of a million pounds is needed for the dedicated centre at Salisbury District Hospital which would be able to treat four and a half thousand women each year. Penny Silvester reports.
There's condemnation from Cancer Charities that a drug which can extend the lives of some women with advanced breast cancer has been rejected for NHS use because it is too expensive.
Kadcyla has shown remarkable success in trials at The Queen Alexandra Hospital in Portsmouth, and a woman from Reading says it's extended her life by three years.
But it costs 90 thousand pounds for a course of treatment, too much for the NHS financial watchdog, NICE, which made the decision. It has criticised the manufacturers for the high cost.
Rachel Hepworth speaks to cancer survivors Manjinder Coulter and Kimberly Mawby, Chief Exec of NICE, Andrew Dillon, Sarah Rawlings from the charity Breakthrough Cancer, and Jennifer Cozzone from pharmaceutical company Roche.
A drug that can extend the lives of some women with an advanced form of breast cancer has been rejected for NHS use because it is too expensive.
The high price of Kadcyla makes it "impossible" to recommend for widespread use in the health service, the National Institute for Health and Care Excellence (Nice) said.
The drug, also known as trastuzumab emtansine, is used to treat breast cancer patients with HER2-positive breast cancer that has spread to other parts of the body. It is used when the cancer cannot be surgically removed and the patient has stopped responding to initial treatments.
It can offer these women a last hope, extending the lives of patients by around six months.
But final draft guidance from Nice says that the drug, which costs around £90,000 per patient at its full price, it too expensive to recommend for widespread use in the health service.